4.3 Review

Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors

Journal

CARDIORENAL MEDICINE
Volume 2, Issue 4, Pages 314-327

Publisher

KARGER
DOI: 10.1159/000343803

Keywords

Obesity; Cardiorenal metabolic syndrome; Cardiovascular disease; Kidney

Funding

  1. NIH [R01 HL73101-01A1, R01 HL107910-01]
  2. Veterans Affairs Merit System [0019]

Ask authors/readers for more resources

The prevalence of obesity has increased rapidly in the United States. Obesity affects about one third of the adult population and, even though it is attributed to excess calorie intake and inadequate physical activity, its etiopathogenesis is much more complex and is an area of active study. Lifestyle modifications (with a focus on increased activity and decreased calorie intake) have modest efficacy in the treatment of obesity. There is a dearth of safe and effective therapeutic modalities to treat obesity. In this review, we discuss the role of different treatment options in the management of obesity and its comorbidities, with a focus on recently approved drugs and the emerging role of bariatric surgery. Copyright (C) 2012 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available